DIQTA 1.0: Drug-Induced QT Prolongation Atlas

OFLOXACIN

DIR Classification Postmarketing Surveillance Drug Property Information Reference

DIR Classification

Classification:Most-DIQT concern

Severity Score:4.0

Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF

PRECAUTIONS
Torsade de Pointes
Some quinolones, including ofloxacin, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia. Rare cases of torsade de pointes have been spontaneously reported during postmarketing surveillance in patients receiving quinolones, including ofloxacin. Ofloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents.
[Other Information]
Patients should be advised:
that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition;
to inform their physician of any personal or family history of QTc prolongation or proarrhythmic conditions such as hypokalemia, bradycardia, or recent myocardial ischemia; if they are taking any class IA (quinidine, procainamide), or class III (amiodarone, sotalol) antiarrhythmic agents. Patients should notify their physicians if they have any symptoms of prolongation of the QTc interval including prolonged heart palpitations or a loss of consciousness.
[Drug Interactions]
Elderly patients may be more sensitive to drug-associated effects on the QT interval. Therefore, precaution should be taken when using ofloxacin with concomitant drugs that can result in prolongation of the QT interval (e.g. Class IA or Class III antiarrhythmics) or in patients with risk factors for torsade de pointes (e.g. known QT prolongation, uncorrected hypokalemia) (see PRECAUTIONS, GENERAL, TORSADE DE POINTES).
MEDICATION GUIDE
Other serious side effects of ofloxacin tablets include:
Serious heart rhythm changes (QT prolongation and torsade de pointes)
Tell your healthcare provider right away if you have a change in your heart beat (a fast or irregular heartbeat), or if you faint. Ofloxacin tablets may cause a rare heart problem known as prolongation of the QT interval. This condition can cause an abnormal heartbeat and can be very dangerous. The chances of this happening are higher in people:
who are elderly
with a family history of prolonged QT interval
with low blood potassium (hypokalemia)
who take certain medicines to control heart rhythm (antiarrhythmics)

Postmarketing Surveillance

Contingency Table:

Current Drug

Other Drugs

QT Prolongation

24087

Other ADRs

4697

38376890

Odds Ratio = 1.697

Drug Property Information

ATC Code(s):

J01MA01 - ofloxacin

J01MA - Fluoroquinolones
J01M - QUINOLONE ANTIBACTERIALS
J01 - ANTIBACTERIALS FOR SYSTEMIC USE
J - ANTIINFECTIVES FOR SYSTEMIC USE

S01AE01 - ofloxacin

S01AE -
S01A - ANTIINFECTIVES
S01 - OPHTHALMOLOGICALS
S - SENSORY ORGANS

S02AA16 - ofloxacin

S02AA - Antiinfectives
S02A - ANTIINFECTIVES
S02 - OTOLOGICALS
S - SENSORY ORGANS

Active Ingredient:OFLOXACIN

Active Ingredient UNII:A4P49JAZ9H

Drugbank ID:DB01165

PubChem Compound:4583

CTD ID:D015242

PharmGKB:PA450684

CAS Number:82419-36-1

Dosage Form(s):tablet, coated

Route(s) Of Administrator:oral

Daily Dose:

400.0 mg/day J01MA01

Chemical Structure:

SMILE Code:
CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1

Reference

1: Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate.

[Liang Li-Yu,He Ying-Chun,Li Yun-Fei,Yang Juan,Xu Feng-Yan,Li Lu-Jin,Huang Ji-Han,Wang Kun,Zheng Qing-Shan]
Biomed Pharmacother,2020 Oct;130:110619. PMID: 32795925

2: Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.

[Thee S,Garcia-Prats A J,McIlleron H M,Wiesner L,Castel S,Norman J,Draper H R,van der Merwe P L,Hesseling A C,Schaaf H S]
Antimicrob Agents Chemother,2014 May;58(5):2948-51. PMID: 24550337

3: A case of levofloxacin-induced anaphylaxis with elevated serum tryptase levels.

[Lee Ji-Ho,Lee Won Yeon,Yong Suk Joong,Shin Kye Chul,Lee Myoung Kyu,Kim Chong Whan,Kim Sang-Ha]
Allergy Asthma Immunol Res,2013 Mar;5(2):113-5. PMID: 23450078

4: Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.

[Zeuli John D,Wilson John W,Estes Lynn L]
Antimicrob Agents Chemother,2013 Mar;57(3):1121-7. PMID: 23229485

5: QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.

[Briasoulis Alexandros,Agarwal Vikram,Pierce Walter J]
Cardiology,2011;120(2):103-10. PMID: 22156660

6: Analysis of Relationship between Levofloxacin and Corrected QT Prolongation Using a Clinical Data Warehouse.

[Park Man Young,Kim Eun Yeob,Lee Young Ho,Kim Woojae,Kim Ku Sang,Sheen Seung Soo,Lim Hong Seok,Park Rae Woong]
Healthc Inform Res,2011 Mar;17(1):58-66. PMID: 21818458

7: [A multi-center, randomized, controlled, double blind and double dummy clinical trial of antofloxacin hydrochloride tablet versus levofloxacin tablet for the treatment of acute bacterial infections].

[Xiao Yong-hong,Cui Hong,Xue Feng,Huang Wen-xiang,Xiu Qing-yu,Li De-tian,Chen Ping,Jia Zheng-ping,Wen Ai-dong,Yang Guo-ping,Mao Guo-guang]
Zhonghua Nei Ke Za Zhi,2011 Mar;50(3):225-9. PMID: 21600087

8: Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.

[Milberg Peter,Hilker Ekkehard,Ramtin Shahram,Cakir Yilmaz,Stypmann Jörg,Engelen Markus A,Mönnig Gerold,Osada Nani,Breithardt Günter,Haverkamp Wilhelm,Eckardt Lars]
J Cardiovasc Electrophysiol,2007 Jun;18(6):647-54. PMID: 17388913

9: Arrhythmias associated with fluoroquinolone therapy.

[Falagas Matthew E,Rafailidis Petros I,Rosmarakis Evangelos S]
Int J Antimicrob Agents,2007 Apr;29(4):374-9. PMID: 17241772

10: Effects of three fluoroquinolones on QT analysis after standard treatment courses.

[Tsikouris James P,Peeters Michael J,Cox Craig D,Meyerrose Gary E,Seifert Charles F]
Ann Noninvasive Electrocardiol,2006 Jan;11(1):52-6. PMID: 16472283

11: Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?

[Makaryus Amgad N,Byrns Kory,Makaryus Mary N,Natarajan Usha,Singer Carol,Goldner Bruce]
South Med J,2006 Jan;99(1):52-6. PMID: 16466123

12: Drug-induced QT prolongation.

[Wooten James M]
South Med J,2006 Jan;99(1):16. PMID: 16466115

13: A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.

[Morganroth Joel,Dimarco John P,Anzueto Antonio,Niederman Michael S,Choudhri Shurjeel,CAPRIE Study Group]
Chest,2005 Nov;128(5):3398-406. PMID: 16304291

14: QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.

[Nykamp Diane L,Blackmon Casey L,Schmidt Paul E,Roberson Andrea G]
Ann Pharmacother,2005 Mar;39(3):543-6. PMID: 15687478

15: Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient.

[Gandhi Pritesh J,Menezes Pearl A,Vu Hien T,Rivera Amy L,Ramaswamy Karthik]
Am J Health Syst Pharm,2003 Dec 1;60(23):2479-83. PMID: 14686224

16: Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.

[Curtis Lesley H,Østbye Truls,Sendersky Veronica,Hutchison Steve,Allen LaPointe Nancy M,Al-Khatib Sana M,Usdin Yasuda Sally,Dans Peter E,Wright Alan,Califf Robert M,Woosley Raymond L,Schulman Kevin A]
Am J Med,2003 Feb 1;114(2):135-41. PMID: 12586234

17: Moxifloxacin: new preparation. A me-too with more cardiac risks.

Prescrire Int,2002 Dec;11(62):168-9. PMID: 12469694

18: Clinical toxicological aspects of fluoroquinolones.

[Stahlmann Ralf]
Toxicol Lett,2002 Feb 28;127(1-3):269-77. PMID: 12052667

19: Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.

[Frothingham R]
Pharmacotherapy,2001 Dec;21(12):1468-72. PMID: 11765299

20: Latest industry information on the safety profile of levofloxacin in the US.

[Kahn J B]
Chemotherapy,2001;47 Suppl 3:32-7; discussion 44-8. PMID: 11549787

21: Comparison of side effects of levofloxacin versus other fluoroquinolones.

[Carbon C]
Chemotherapy,2001;47 Suppl 3:9-14; discussion 44-8. PMID: 11549784

22: History of quinolones and their side effects.

[Rubinstein E]
Chemotherapy,2001;47 Suppl 3:3-8; discussion 44-8. PMID: 11549783

23: A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.

[Martin S J,Jung R,Garvin C G]
Drug Saf,2001;24(3):199-222. PMID: 11347723

24: Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

[Kang J,Wang L,Chen X L,Triggle D J,Rampe D]
Mol Pharmacol,2001 Jan;59(1):122-6. PMID: 11125032

Search for drugs: